Viewing Study NCT00132626



Ignite Creation Date: 2024-05-05 @ 11:48 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00132626
Status: COMPLETED
Last Update Posted: 2019-04-03
First Post: 2005-08-18

Brief Title: Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
Sponsor: Institute for Neurodegenerative Disorders
Organization: Institute for Neurodegenerative Disorders

Study Overview

Official Title: Dynamic SPECT Imaging With 123Iß-CIT in Patients With Parkinsonism
Status: COMPLETED
Status Verified Date: 2019-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study assesses dopamine transporter density using single photon emission computed tomography SPECT brain imaging with an investigational radiopharmaceutical 123Iß-CIT in research participants with Parkinsons disease
Detailed Description: The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven Connecticut The imaging procedure occurs over a two day period

After a screening visit including review of the potential subjects neurological history and a thorough neurologic exam subjects are injected with 123Iß CIT an investigational radioactive material that localizes in the brain

Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT single photon emission computed tomography images of the brain

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None